Asset profile
AND017
Small molecule
Evidence outlook · registrational
Chronic Kidney Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2026-10-30.
NCT05265325: The study was randomized, triple-blind, and active-controlled, with 175 participants assigned to AND017 or standard erythropoiesis-stimulating therapy. However, the registry does not report whether the primary endpoints—adverse-event incidence and mean hemoglobin change at Week 6—were met, so the findings cannot be judged as demonstrating a positive effect.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 25 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AND017: this drug | Phase 3 | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Vadadustat (Vafseo) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Desidustat (Oxemia) | Phase 3 | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Enarodustat | Phase 3 | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Molidustat | Phase 3 | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Roxadustat (Evrenzo) | Phase 3 | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| SSS17 | Phase 2 | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (4)
October 2026 (1)
What to watch
December 2026 (3)
What to watch
What to watch
What to watch
2027 (1)
December 2027 (1)
What to watch
2028 (1)
May 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.